How effective is ruxolitinib tablets/ruxolitinib in the treatment of myelofibrosis?

Ruxolitinib tablets/ruxolitinib (JAKAVI) is an oral inhibitor targeting the JAK1 and JAK2 pathways. It is mainly used to treat intermediate and high-risk myelofibrosis (MF), including primary myelofibrosis and myelofibrosis secondary to polycythemia vera or thrombocythemia. Its therapeutic mechanism is different from traditional chemotherapy or hormone drugs. Ruxolitinib mainly reduces the inflammatory response of abnormal hematopoietic cells by regulating the JAK-STAT signaling pathway, thereby alleviating a series of clinical symptoms caused by myelofibrosis. For many patients, myelofibrosis is often accompanied by chronic symptoms such as obvious spleen enlargement, fatigue, weight loss, night sweats, and bone pain. The introduction of ruxolitinib provides a new way of alleviating such diseases.

Judging from overseas treatment experience, ruxolitinib has shown stable advantages in improving patients' quality of life. Its effect is not limited to reducing the size of the spleen, but more importantly, it can significantly alleviate the systemic inflammatory response caused by bone marrow abnormality. Many patients reported that after taking the medicine for several weeks, their physical discomfort was significantly reduced, and their appetite and mental state were improved to varying degrees. Although ruxolitinib cannot completely reverse the pathological process of myelofibrosis, it is of great significance in delaying disease progression, controlling clinical symptoms, and reducing dependence on blood transfusions.

It should be noted that the use of ruxolitinib is not without side effects. Some patients may experience the risk of anemia, thrombocytopenia, or immunosuppression-related infections during the early stages of taking the drug, so doctors will adjust the dose based on the patient's blood picture and clinical manifestations. In the long-term management of myelofibrosis, ruxolitinib is more like a drug with "slow regulation and steady control", and its real value is reflected in the systemic benefits after long-term standardized use.

Reference materials:https://www.jakavi.com/